Twice as many patients stopped taking Pfizer's anti-blood clotting drug Fragmin because of death compared with those taking another anti-clotting treatment, FDA reps said in a report released on Tuesday.
Fragmin has been on the the U.S. market since 1994 and is approved for short-term use in patients undergoing certain types of abdominal and hip replacement surgery. The drug is also approved for long-term use in patients with certain heart conditions along with aspirin therapy.
Pfizer will ask a U.S. Food and Drug Administration advisory panel to back wider use of Fragmin for treating and preventing blood clots in cancer patients. The drug is already approved for treating blood clots in abdominal surgery patients, among others.
From Reutuers and Yahoo.com
